Expression and characterization of a soluble VEGF receptor 2 protein by Wei Liu et al.
Cell & Bioscience
Liu et al. Cell & Bioscience 2014, 4:14
http://www.cellandbioscience.com/content/4/1/14RESEARCH Open AccessExpression and characterization of a soluble VEGF
receptor 2 protein
Wei Liu1,2, Xinyuan Zhang1*, Ching Song2, Shisan Bao3, Donna Lai4, Jianqiu Mou2, Tao Jiang5 and Ningli Wang1Abstract
Objective: To clone and express a truncated, soluble vascular endothelial growth factor receptor 2 (sVEGFR2)
possessing the combined-functional domains 1–3 and 5 in eukaryotic cells and to test the inhibitory effects of full
length VEGFR2 in vivo.
Results: pCMV6-trunctated-rVegfr2 (6100 bp) was successfully cloned. The transfection experiments showed that either
pCMV6-truncated-rat-Vegfr2 (pCMV6-truncated-rVegfr2) or pCMV6-rVegfr2 inhibited the expression of intracellular green
fluorescent protein, which is usually used as an exogenous transfected reporter gene to determine the transfected
efficiency. An analysis of the transfected cells revealed that the amount of full-length VEGFR2 protein in the
pCMV6-truncated-rVegfr2 transfected cells was 20% lower than that in the negative control (non-transfected HEK
293 cells). The differences in test results between the transfected and negative control groups were greatest from
24–30 h after transfection; this period was therefore chosen as optimal for collecting culture supernatants. This
analysis was highly sensitive for detecting the amount of sVEGFR2 protein expressed and secreted by the cells, and
the sVEGFR2 protein content was found to increase by approximately 26% in the transfected cells compared to
that in the negative control cells (68.2% ± 1.7% vs. 41.9% ± 2.9%, P = 0.000) and by 18% compared to the negative
control cells (68.2% ± 1.7% vs. 50.0% ± 0.5%, P = 0.003). Propidium iodide and Hoechst staining indicated no significant
change in the number of HEK293 cells undergoing apoptosis 6 days after pCMV6-trucated-Vegfr2 transfection,
compared to the negative control. Soluble VEGFR2 produced by pCMV6-truncated-rVegfr2 inhibited full-length
VEGFR2 protein expression in the cell membrane.
Conclusions: This study employed a eukaryotic system to express sVEGFR2. The use of transient transfection
technology greatly improved transfect efficiency. Recombinant sVEGFR2 inhibited the effect of endogenous
full-length VEGFR2 but was not cytotoxic.
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Vascular endothelial growth factor A (VEGFA), a polypep-
tide growth factor, originally discovered as a permeability
factor is now accepted as an inducer of angiogenesis and
vascular leakage both in vitro and in vivo [1-3]. VEGF acts
by binding with its receptors (VEGFR), promoting receptor
dimerization and tyrosine auto-phosphorylation. This leads
to a kinase cascade in the cell membrane/cytoplasm that
transmits a signal to the cell nucleus, inducing a series of
changes. VEGFRs are trans-membrane proteins comprised* Correspondence: mmzxy2010@163.com
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mains, an intracellular tyrosine kinase domain and a
trans-membrane sequence.
Members of the VEGFR family include VEGFR1,
VEGFR2, and VEGFR3. Among these receptors, VEGFR2
is recognized as the key down regulator for VEGFA’s
pathological effects [4]. Vascular leakage, angiogenesis
and neuronal degeneration are three features of diabetic
retinopathy. VEGFA is a critical driver in these processes,
acting as a vascular leakage inducer, angiogenesis mediator
and neuron protector in diabetic retinopathy. The VEGF-
VEGFR2 pathway was found to play a key role in diabetic
retinopathy. Blockage of the VEGF-VEGFR2 pathway may
represent a novel therapeutic strategy to reduce vascular
leakage and angiogenesis in diabetic retinopathy.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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length Vegfr2 (long form, 1343 aa) encoded by the rat is
similar to humans. A C-terminal truncated version of
the protein (991 aa) was found to be encoded by a short
form of the vegfr2gene [3]. We also demonstrated that
the long formVEGFR2 is the predominant receptor for
VEGF-A in the rat retina, while in comparison the
truncated form of VEGFR2 is expressed at very low levels
in both normal and diabetic retinas. We further found that
the long form of VEGFR2 is the predominant mediator of
VEGF-A in the pathogenesis of diabetic retinopathy (DR)
and can be significantly inhibited by intravitreal steroid
treatment. The short form, which cannot be phosphory-
lated, does not appear to contribute to the pathogenesis of
DR. We proposed that the truncated form of Flk-1 could
be used clinically as a dominant negative inhibitor of the
effects of VEGF [3].
The extracellular segment of VEGFR2 includes the VEGF
ligand binding site. More specifically, the VEGFR2 Ig
domain 1 is necessary for VEGF binding, while Ig domains
2–3 ensure a tight bond with VEGF. The receptor employs
Ig domain 4 to create the active form of the homologous
dimer, whereas Ig domains 5–7 are not closely associated
with VEGF binding [5]. Based on our previous findings,
we aimed to express a new truncated VEGFR2 by digesting
a full-length rat Vegfr2-encoding plasmid to produce a
fragment that would encode VEGFR2 Ig domains 1–3
and 5.
Results
Sub-cloning of plasmid pCMV6-truncated-rat-Vegfr2
The pCMV6-rat-Vegfr2 (pCMV6-rVegfr2) plasmid con-
sisted of a 4.2-kb rat-Vegfr2 ORF and a 4.9-kb pCMV6-
Entry vector, which were tagged with Myc and DDK, and
contained an EcoRV restriction enzyme site, respectively.
pCMV6-rVegfr2 was truncated with EcoRV to remove a
3006-bp gene segment and retain the region that encodes
the rVEGFR2 Ig1–3 and5 extracellular soluble proteins,
followed by analysis with CLC Sequence Viewer 6.8 software
(Figure 1). Following digestion, ligation, transformation
and replication in E.coli, the plasmids were extracted
and screened for the target plasmid via 0.8% agarose gel
electrophoresis. Plasmids were truncated with EcoRV to
identify the gene fragment of a size that coincided with
the expected target gene fragment size. ORF of the vegfr2
gene and a single 6.1-kb DNA fragment were confirmed
by sequencing, indicating that the pCMV6-truncated-
rVegfr2 plasmid vector had been constructed successfully
(Figure 2).
Transient transfection
Transient transfection of the exogenous plasmids pCMV6-
truncated-rVegfr2 and pCMV6-rVegfr2 into HEK293
cells was performed according to the liposome preparationprotocol with a reporter gene pCMV-gfp (0.10 μg/well).
To avoid artifact caused by different DNA concentrations,
a pCMV/R-luc plasmid was added to the wells to achieve
the same concentration. Three groups were generated,
the rVegfr2, truncated-rVegfr2 and negative control (non-
transfected) groups. The plasmids were transfected into
HEK293 cells for 48 h and observed under an inverted
fluorescence microscope (Figure 3). To normalize the
transfection efficiencies between different groups, GFP
protein expression was semi-quantitatively analyzed. For
both the rVegfr2 and truncated-Vegfr2 groups, GFP ex-
pression decreased with an increase in the desired plasmid
concentration. No difference in GFP expression was ob-
served in the rat-Vegfr2 group or truncated-Vegfr2 group
at the same time point, however, both in rVegfr2 and
truncated-Vegfr2 groups, GFP expression levels decreased
over time, it may result from the increased VEGFR2
expression levels over time.propidium iodide (PI) and
Hoechst-labeled cells in the different groups were exam-
ined 72 h after transfection (Figure 4). Hoechst 33342
brightly stains the condensed chromatin of apoptotic cells
and dimly stains the normal chromatin of live cells. So,
while Hoechst stained the entire cell population, more in-
tense staining was observed for apoptotic cells and dead
cells. PI cannot permeate into live cells, meaning only
dead cells were stained red with PI. There were no signifi-
cant differences in the frequencies of PI-labeled apoptotic
cells and the cell densities in the rVegfr2 and truncated-
rVegfr2 groups, compared with the negative control group
(non-transfected cells), as observed via fluorescent micros-
copy. The expression of GFP decreased with increasing tar-
get plasmid concentrations, suggesting a high transfection
efficiency for pCMV6-truncated-rVegfr2.
Large numbers of living cells remained after a 6-day
transfection period. GFP expression was also detected in
all of the transfected cells (Figure 5). Differences in the
transfection rates are summarized in Table 1. There was
a significant difference in the transfection rate for the
rat-Vegfr2 0.15 group (0.15ug DNA/well), compared with
that of the control group (12.3% ± 2.3% vs. 16.8% ± 0.8%,
P = 0.022). The difference in transfection rates between
the experimental groups (F ratio = 2.192, P = 0.150) was
not statistically significant. Transfection efficiencies in-
creased in the HEK293 cells using higher concentrations
of pCMV6-truncated-rVegfr2 plasmids. The apoptotic index
(AI) is much lower in the 0.05 truncated-rVegfr2, 0.1trun-
cated-rVegfr2 and 0.05 rVegfr2 groups, compared to the
control group (22.1% ± 2.2% vs. 29.5% ± 1.0%, P = 0.003;
16.2% ± 2.6% vs. 29.5% ± 1.0%, P = 0.000 and 23.1% ±
3.1% vs. 29.5% ± 1.0%, P = 0.014, respectively). Further,
there were no significant differences between the 0.15
truncated-rVegfr2 and 0.10 rVegfr2 group, compared
to the control group (AI = 26.4% ± 3.0% vs. 29.5% ± 1.0%,
P = 1.000 and 32.2% ± 2.7% vs. 29.5% ± 1.0%, P = 1.000,
Figure 1 Schematic of the recombinant plasmid pCMV6-truncated-rVegfr2. Restriction digestion of the two EcoRV restriction sites in the
plasmid pCMV6-rVegfr2, which encodes the extracellular reserved VEGFR2 Ig 1–3 and 5 regions. The recombinant plasmid pCMV6-truncated-rVegfr2
was reconstructed after self-ligation of the plasmid vector with T4 DNA ligase. rVegfr2: rat-Vegf-receptor2.
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of pCMV6-truncated-rVegfr2/pCMV6-rVegfr2 for trans-
fection might attenuate apoptosis. When the plasmid
concentration was increased to 0.10, the protective effect
disappeared; however, the proteins were not cytotoxic.Figure 2 Electrophoretic analysis of pCMV6-rVegfr2 subcloning. Lane 1:
bp respectively. Lane 2: pCMV-rVegfr2 plasmid. Lane 3: Marker DNA. Lane 1: m
VEGFR2 enzyme products (12200 bp). B: an open-loop-shaped pCMV6-trunca
rVegfr2: rat-Vegf-receptor2.Quantitative analysis of the target protein via ELISA
VEGFR2 protein concentrations in the cell culture su-
pernatants were determined with a VEGFR2-ELISA kit.
Supernatant from the serum-free DMEM medium group
was used as the negative control. We found that in thethe two interconnected VEGFR2 enzyme products are 6100 bp and 3006
arker DNA. Lane 2: pCMV-rVegfr2 plasmid. Lane 3: A: two interconnected
ted-Vegfr2 plasmid. C: sub-cloned pCMV6-truncated-rVegfr2 (6100 bp).
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Figure 3 GFP expression in pCMV6-rVegfr2- or pCMV6-truncated-rVegfr2-transfected HEK293 cells. 48 hours after HEK293 cells were
co-transfected with the pCMV-gfp plasmid and pCMV6-truncated-rVegfr2 or pCMV6-rVegfr2 plasmids, GFP expression was examined under an
inverted fluorescence microscope with a 10x objective. The concentration of transfected pCMV-gfp DNA was consistent in all experimental groups
(0.10 μg/well and 4 × 104cells/well). A, Control group (transfected with 0.1ug/well pCMV-gfp only). B-D, transfected pCMV6-truncated-rVegfr2
plasmid with three different concentrations E-G, transfected pCMV6-rVegfr2 plasmid with three different concentrations. rVegfr2: rat-Vegf-receptor2.
Scale bar: 1000 um.
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in the cell culture supernatant decreased along with an in-
crease in the amount of transfected plasmids. In the groups
transfected with lower plasmid concentrations (0.05 μg/well
and 0.10 μg/well), the amount of sVEGFR2 extracellular
protein fragment expression was very low. Therefore,
we infer that 0.15 μg/well is the optimal target plasmid
transfection concentration. In the rat-Vegfr2 group, there
was no association between the concentrations of the
transfected pCMV6-rVegfr2 and the extracellular secreted
protein (Figure 6).
To increase the amount of extracellular-secreted VEGFR2
protein and optimize the incubation time, we collected
the cell culture supernatants for ELISA at different timeA
B
E
Figure 4 Transfection efficiencies and apoptotic indices of the pCMV6
cells were co-transfected with pCMV-gfp (0.10 μg/well) and pCMV6-rVegfr
Hoechst staining were performed at 72 h after transfection in each experimen
B-D, transfected pCMV6-truncated-rVegfr2 plasmid with three different conce
with three different concentrations. rVegfr2: rat-Vegf-receptor2. Scale bar: 1000points. Within 24–30 h after transfection, the VEGFR2
protein concentration in the supernatant was higher in
the truncated-Vegfr2 and rat-Vegfr2 groups, compared
with the negative control group (255.1 ± 36.1 pg/ml vs.
71.9 ± 50.8 pg/ml, P = 0.010 and 215.4 ± 72.2 pg/ml vs.
33.3 ± 5.4 pg/ml, P = 0.010, respectively). The time
period from 24–30 h after transfection was selected as
the optimal time for cell culture supernatant collection.
There were no significant differences between the other
time points (P > 0.05), although an increasing trend was
observed in the experimental groups, compared with the
negative control group (Figure 7). The target protein con-
centration was higher at 45 h post-transfection than at 24 h
and 30 h in the negative control group (210.5 ± 8.5 pg/mlC D
F G
-rVegfr2- and pCMV6-truncated-rVegfr2- HEK293 cells. HEK293
2 or pCMV6-truncated-rVegfr2 plasmids (4 × 104cells/well). PI and
tal group. A, Control group (transfected with pCMV-gfp plasmid only).




Figure 5 HEK293 cells were stained and observed at a high magnification (× 20) at 6 days post-transfection. HEK293 cells were cells cultured
and stained with PI and Hoechst dye at 6 days after transfection. The seeding density was consistent in all experimental groups (4 × 104cells/well).
A, HEK293 cells transfected with pCMV6-rVegfr2 plasmid (0.15 μg/well plus pCMV-gfp plasmid (0.10 μg/well); B, HEK293 cells transfected with
pCMV6-truncated-rVegfr2 plasmid at 0.15 μg/well plus pCMV-gfp plasmid (0.10 μg/well; and C, control group (HEK293 cells transfected with
pCMV-gfp plasmid (0.10 μg/well)). rVegfr2: rat-Vegf-receptor2. Scale bar: 200 um.
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F ratio = 19.451, P = 0.019). This difference might be
caused by interference from the VEGFR2 proteins released
from the membrane, and the degradation of the protein
over time. At the median time point, the extracellular
VEGFR2 protein was somewhat degraded.
To determine whether the VEGFR2 protein accumu-
lated inside the transfected cells, we detected intra- and
extracellular VEGFR2 protein concentrations via ELISA.
The protein concentration in the non-transfected cell
group was regarded as the intracellular VEGFR2 protein











points 303.2 ± 19.1 324.8 ± 28.5 387.2 ± 14.5
Red fluorescent
points 532.2 ± 17.8 452.4 ± 54.6 311.2 ± 20.5
Blue fluorescent
points 1272.0 ± 49.5 1593.6 ± 116.6* 1640.0 ± 256
Transfection rate
of GFP (%) 16.8 ± 0.8 15.9 ± 1.6 20.1 ± 2.5
Apoptotic index (%) 29.5 ± 1.0 22.1 ± 2.2* 16.2 ± 2.6*
*P < 0.05(Compared with the normal control group) cells were stained with PI and
Green fluorescent points: the number of pCMV-gfp-transfected HEK293 cells.
Transfection efficiency: the number of green fluorescence-positive cells/ the numbe
Apoptosis index: the number of PI-positive cells/the number of Hoechst-stained cel
rVegfr2: Rat-Vegfr2.was normalized between the transfected groups and the
non-transfected control. The supernatant from serum-free
DMEM medium was used as the negative control. The
results indicated that the intracellular VEGFR2 concen-
tration was significantly lower in the truncated-rVegfr2
group than in the control group (42.4 ± 3.4 pg/ml vs.
58.3 ± 2.4 pg/ml, P = 0.093). The VEGFR2 concentration
was higher in the rat-Vegfr2 group than in the control
group (62.9 ± 4.6 pg/ml vs. 58.3 ± 2.4 pg/ml, P = 1.000),
but this difference was not significant. There was a signifi-
cant difference in the intracellular protein concentration












* 216.0 ± 23.3* 272.2 ± 13.1 261.8 ± 17.0* 142.4 ± 15.8*
446.6 ± 44.2* 307.8 ± 34.1* 443.0 ± 48.6* 149.2 ± 35.6*
.9 1252.0 ± 151.3 1029.6 ± 76.9 932.0 ± 55.8* 1030.4 ± 135.9
12.8 ± 2.3 20.4 ± 1.6 19.1 ± 2.1 12.3 ± 2.3*
26.4 ± 3.0 23.1 ± 3.1* 32.2 ± 2.7 12.8 ± 3.2*
Hoechst.
r of living cells (Hoechst-stained cells).
ls.
Figure 6 Effect of the DNA amount on the VEGFR2 concentration in the culture supernatant. Liposome and plasmid DNA were added at a
1:1 (w/w) ratio, HEK293 were plated at 4 × 104 cells/well, and the DNA concentration ranged from 0–0.15 μg/well.
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The extracellular protein concentrations were higher
in the truncated-rVegfr2 and rVegfr2 groups than that
in the control group (90.8 ± 10.0 pg/ml vs. 42.0 ± 6.4
pg/ml, P = 0.0001 and 62.9 ± 5.5 pg/ml vs. 42.0 ± 6.4
pg/ml, P = 0.015, respectively). There was a significant
difference in the extracellular protein concentration
between the truncated-Vegfr2 and rVegfr2 groups (90.8 ±
10.0 pg/ml vs. 62.9 ± 5.5 pg/ml, P = 0.001). The pCMV6-
truncated-rVegfr2-transfected cells were stimulated to
secrete large amounts of sVEGFR2 protein fragment,
resulting in increases in the percentages of extracellular
secreted protein production of 18% and 26% over those
of the rVegfr2 and negative control groups, respectively
(68.2% ± 1.7% vs. 50.0% ± 0.5%, P = 0.003 and 68.2% ±
1.7% vs. 41.9% ± 2.9%, P = 0.000, respectively) (Figure 8).Figure 7 VEGFR2 expression levels in serum-free DMEM culture super
DNA were added in a 1:1 (w/w) ratio to HEK293 (seeding density 4 × 104 c
pCMV6-truncated-rVegfr2 DNA plus 0.10 μg pCMV-gfp/well. rVegfr2 indicat
indicates transfection of 0.10 μg pCMV-gfp/well alone. rVegfr2: rat-Vegf-recDiscussion
Several anti-VEGF/VEGFR therapeutic strategies have
been developed, including the use of soluble receptors,
VEGF and VEGFR-neutralizing antibodies. Other inhibi-
tors that target both VEGF and VEGFRs such as small
molecules or antisense oligodeoxynucleotides that inhibit
VEGFR signal transduction have also been explored. When
used alone or in conjunction with other drugs, these
methods can be utilized to treat malignant tumors and
other diseases. Research has shown that soluble high-
affinity VEGFR2 fragments are therapeutically effective
[6,7]. Soluble VEGFR2 fragments can bind endogenous
VEGF, thereby blocking the action of VEGF and impeding
the binding of VEGFR1, VEGFR2, and VEGFR3 to cell
membrane ligands, inhibiting the VEGF-induced signaling
pathway, and preventing angiogenesis [8].natants at different time points after transfection. Liposome and
ells/well). Truncated-rVegfr2 indicates transfection of 0.15 μg of
es 0.15 μg of transfected DNA plus 0.10 μg pCMV-gfp/well. Control
eptor2. *: P < 0.05.
Figure 8 Intracellular and extracellular VEGFR2 protein concentrations in HEK293 cells under different transfection conditions. ELISA
was used to detect the intracellular and extracellular VEGFR2 protein concentrations in HEK293 cells. Liposomes and DNA were added at a 1:1
(w/w) ratio to HEK293 (seeding density 4 × 104 cells/well). Truncated-Vegfr2 indicates transfection with 0.15 μg of pCMV6-truncated Vegfr2 plasmid
plus 0.10 μg pCMV-gfp plasmid/well. Rat-Vegfr2 indicates transfection with 0.15 μg of pCMV6-rVegfr2 plasmid plus 0.10 μg pCMV-gfp/well. Control
indicates transfection of 0.10 μg/well pCMV-gfp alone. rVegfr2: rat-Vegf-receptor2. *: P < 0.05.
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III transmembrane protein kinase that was first discovered
in 1991 [9]. The VEGFR2 gene locus is found on chromo-
some 4q11-q12, and it encodes a receptor with a total
length of 1,443 amino acids. VEGFR2 is translated into an
intracellular non-glycosylated protein of approximately
150 kDa, that is subsequently repeatedly glycosylated,
to yield a mature form of approximately 230 kDa that
localizes to the cell membrane.
Our previous work demonstrated that though there
are two isoforms of VEGFR2 found in rat, the long form
of vegfr2 gene share 99.9% identity of gene sequence
with human’s. Given that humans have only a single
isoform, we have chosen to express and characterize
rat truncated VEGFR2 in this study ahead of further in vivo
testing.
Catalysis is facilitated by an extracellular structural do-
main that contains seven immunoglobulin-like domains,
a transmembrane structural domain, and a cytoplasmic
tyrosine kinase structural domain. Signal transduction is
chiefly mediated by the specific binding of VEGF to the
extracellular regions I–III of VEGFR2 [10,11].
Previous studies have only tested a soluble VEGFR2
(sVEGFR2) protein that contained Ig domain 3 (97 amino
acids) and have consequently overlooked the regulation
of receptor-ligand binding by Ig domains 1 and 2, which
reduces the affinity of sVEGFR2 for VEGF. This study
employed restriction enzyme digestion in conjunction with
the recombinant cloning of a Norway rat Vegfr2 gene
restriction fragment into the eukaryotic expression vector
pCMV6. The end product was a pCMV6-diagested-Vegfr2plasmid encoding a form of sVEGFR2 that contained Ig
domains 1–3 and 5 of the rat VEGFR2 protein.
Most research on the preparation of sVEGFR proteins
has employed recombinant target plasmids to induce target
protein expression in an IPTG prokaryotic expression
system. However, this process leads to many problems,
such as severe cytotoxicity of the expression products,
failure to glycosylate the protein product, and failure to
achieve correct target protein folding [12,13]. Reports have
indicated that most laboratories relied on Escherichia coli
expression systems to induce sVEGFR1 and sVEGFR2
expression and that the anti-angiogenic efficacies of these
expression products was less than 40% [14]. This low level
was because E. coli usually expresses 50% of the total pro-
tein, and rapid bacterial expression leads to either a failure
to fold or incorrect folding. These problems are particularly
common in proteins that require long expression times
such as heterogeneous proteins or those with molecular
companions. The transient transfection method ensures
that the exogenous genes exist only in free plasmid vectors
after target cell transfection. The plasmids do not integrate
into the chromosomes. Consequently, the target gene
expression products can be obtained in a short time;
however, as the cells proliferate, the exogenous genes
ultimately disappear. The expression process can continue
for several days or up to 2 weeks. This method can greatly
shorten the process of recombinant protein production
and thus provides a rapid and convenient gene expression
method. In addition, we co-transfected, the reporter
pCMV-gfp plasmid with the target plasmids for transfec-
tion condition optimization.
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plate at 80–90% confluency. However, given the relatively
long experimental period, the cells invariably became fully
confluent within 24 h of transfection. The cells also under-
went apoptosis due to overgrowth during the observation
stage, thus influencing subsequent observations and testing.
We therefore reduced the required cell density to 50–60%
confluency at the time of transfection, although this
procedure resulted in lower cell transfection efficiencies
and reduced target protein expression. Regarding ELISA
analysis, we initially chose to use a VEGFR2 ELISA Kit to
test the culture supernatants after the cells had been cul-
tured in DMEM with 10% fetal bovine serum (FBS). How-
ever, as the background values were higher in the control
group than the experimental group, we concluded that
miscellaneous proteins in the FBS had severely interfered
with the test results, and therefore, the cultures were
performed in serum-free DMEM. Given the need for
growth factors in the medium, 1 × 10−4 v/v EGF was
added to ensure cell survival.
Regarding the pCMV6-sVegfr2 plasmid obtained by sub-
cloning, we discovered that differences in transfection effi-
ciencies of pCMV6-truncated-rVegfr2 or pCMV6-rVegfr2
in the cells caused different green fluorescent protein
expression levels in the cells. This discrepancy might
have been due to inhibited GFP expression caused by
exogenous target plasmid (pCMV6-truncated-rVegfr2
or pCMV6-rVegfr2) transfection and expression. While
the exogenous plasmid transfection efficiencies were largely
identical among the experimental groups, the transfection
of HEK293 cells with large amounts of pCMV6-rVegfr2 led
to reduced transfection efficiency. Transfection with a
lower concentration of either pCMV6-truncated-rVegfr2
or pCMV6-rVegfr2 had a protective effect on the cells,
inhibiting apoptosis. When the target plasmid concentra-
tion was increased, this protective effect was lost but the
expressed protein was not cytotoxic. While transfection
with pCMV6-truncated-Vegfr2 induced HEK293 cells
to express truncated-VEGFR2 protein, the amount of
pCMV6-rVegfr2 transfected into the cells did not closely
correlate with the amount of truncated-VEGFR-2 secreted
into the culture medium. The differences in the results
between the transfection and control groups were great-
est from 24–30 h after transfection. This period was there-
fore chosen as the optimal time for culture supernatant
collection. Cells in the control and study groups exhibited
poor growth at 45 h after plasmid transfection. This may
have been due to the release of membrane-associated
VEGFR2 protein into the culture medium; the protein
fragments were thus degraded as the culture time in-
creased, and the secreted sVEGFR2 in the culture medium
tended to decompose. Transient transfection with different
exogenous plasmids influenced sVEGFR2 protein expres-
sion and secretion both inside and outside cells. pCMV6-truncated-rVegfr2-transfected cells expressed and secreted
both the soluble VEGFR2 protein and soluble VEGFR2
protein fragments at high efficiencies. The amount of
sVEGFR2 protein secreted by cells in the sVEGFR2
group, as a percentage of all intracellular and extracellular
VEGFR2 protein, increased by nearly 10%, compared to
that secreted by cells in the soluble VEGFR2 group, and
by more than 20% compared to that secreted by cells
in the control group. We propose that pCMV6-rVegfr2
induced copious VEGFR2 protein expression on the
cell membrane; however, the limited ability of the cell
membrane to bind this protein allowed the excess release
of receptor protein fragments into the culture medium.
In contrast, VEGFR2 protein expression on the cell
membrane was lower in the control group, and the posi-
tive results obtained when testing the culture supernatant
might have been caused by the release of VEGFR2 recep-
tor protein fragments from the cell membrane when the
cells underwent apoptosis.
Given the limitations on the number of cells per well,
the reduced plate coverage after transfection, and the
degradation of sVEGFR2 during the culture process, this
study obtained a relatively low target protein yield. Subse-
quent studies should aim to inhibit protein degradation,
ease the cell culture and protein expression restrictions,
and perform specific testing of the sVEGFR2 protein with
the ultimate goal of purifying and testing its biological
activity.
After transfecting cells with pCMV2-trucated-rVegfr2,
we were able to obtain serum-free DMEM culture su-
pernatants containing VEGFR2 protein fragments that
bound to VEGF. This work will provide a basis for the
development of soluble receptors that target endogen-
ous VEGF and treatments for diabetic retinopathy that
target VEGFR2.
Materials and methods
Cell lines and reagents
HEK293 cells were purchased from the Cancer Institute
of the Chinese Academy of Medical Sciences Cell Bank.
The E. coli DH5α strain was from our laboratory. The
restriction endonuclease EcoRV and T4 DNA Ligase
were obtained from Takara China (TAKARA Biotechnol-
ogy Co., LTD., Dalian, Shangdong China). pCMV6-rVegfr2
was constructed by ORIGENE (ORIGENE, China). The
mini-plasmid extraction kit, plastic recycling plasmid
extraction kit, and endotoxin-free plasmid extraction kit
were purchased from TIANGEN China (Tiangen, Beijing,
China). Dulbecco’s modified Eagle’s medium (DMEM)
powder and fetal bovine serum (FBS) were purchased
from Gibco Life Technologies (New York, NY, USA).
Epidermal growth factor (EGF) was obtained from Sino
Biological, Inc (Beijing, China). The rat VEGFR2 ELISA
Kit was purchased from Shanghai Yuanye Biological, Inc
Liu et al. Cell & Bioscience 2014, 4:14 Page 9 of 10
http://www.cellandbioscience.com/content/4/1/14(Shanghai, China). Deionized distilled water was utilized
throughout the entire study.
Methods
Construction of the recombinant plasmid
pCMV6-truncated-rVegfr2
The plasmid pCMV6-rVegfr2 was constructed according to
the nucleotide sequence published in GenBank (GenBank
accession number NM_013062.1). pCMV6-rVegfr2 was
truncated with the restriction endonuclease EcoRV in a
mixture containing 2.5 μl of EcoRV, 5 μl of 10× H Buffer,
30 μl of pCMV6-rVegfr2 DNA, and 12.5 μl of nuclease-
free water; the digestion mixture was incubated overnight
at 37ºC. The product was detected using 0.8% agarose gel
electrophoresis. The 6100 bp fragment in the gel was
recycled and extracted. pCMV6-truncated-rVegfr2 (which
encodes VEGFR2 Ig domains 1–3 and 5) was recombined
using T4 DNA Ligase in a mixture containing 2 μl of
T4 DNA Ligase, 40 μl of recovered plasmid DNA, 5 μl
of 10× buffer, and 3 μl of deionized distilled water, the
mixture was incubated at 4ºC overnight. The recombinant
vector was then transformed into the cloning host strain
E. coli DH5α. Ligation mixture was then transformed into
E. coli. The recombinant plasmids were purified and
detected using 0.8% agarose gel electrophoresis. A large
amount of the recombinant vector pCMV6-truncated-
rVegfr2 was extracted using an endotoxin-free plasmid ex-
traction kit according to the manufacturer’s instructions,
and the OD260/OD280 ratio was measured with a UV
spectrophotometer.
Transient transfection and expression
HEK293 cells were cultured in DMEM (17.8 mM
NaHCO3, 10% FBS, 1/104 v/v of EGF) at 37ºC in 5%
CO2. The cells were plated at a density of 4 × 10
4 cells/well
in 48-well plates and incubated for 24 h. The plasmids
pCMV6-truncated-rVegfr2/pCMV6-rVegfr2, pCMV-gfp,
and pCMV/R-luc (expressing ocean intestinal lumen
luciferase) were transiently transfected into HEK293
cells and the culture medium was discarded and re-
placed with 250 μl/well of serum-free DMEM medium
containing 1/104 v/v EGF, the cells were incubated at
37°C for 48 h to 6 d. The cells were stained with PI and
Hoechst dye and observed under an inverted fluorescence
microscope.
ELISA
HEK293 cells were transfected with different plasmids
and incubated at 37ºC 5% CO2 for 72 h, as described pre-
viously [15]. The supernatants were carefully collected
and centrifuged at 3,000 rpm for 10–20 min to allow de-
tection of the extracellular VEGFR2 protein concentra-
tions with Rat VEGFR2 protein ELISA kits. ELISA
absorbance was measured at 450 nm.Quantification and statistical analysis
Fluorescent cells were counted at 40× magnification and
analyzed with Image J software. The quantitative analyses
were performed at least three times. All data are presented
as means ± SEM. A one-way ANOVA was performed for
the statistical analysis (SPSS, version 16.0; IBM, USA).
The mean values for the groups were compared with
ANOVA, and pairwise comparisons between the groups
were performed with the LSD-t test. A P-value < 0.05 was
considered significant.
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